Y. Loriot

Statistics

Publications

Citations

168

H-Index

Active since

2014

Affiliations

Institut Gustave Roussy(Current)

Icahn School of Medicine at Mount Sinai

Klinikum Stuttgart

Hospital Universitario Virgen del Rocío

Astellas Pharma (United States)

Y. Loriot is an author at Institut Gustave Roussy specializing in metastatic disease treatment, oncology, and metastatic castration-resistant prostate cancer.

Publications per year

2014–2025

Publications

Docetaxel rechallenge after an initial good response in patients with metastatic castration‐resistant prostate cancer

Stéphane Oudard, Gero Kramer, Orazio Caffo et al. · British Journal of Urology · 2014 · 58 citations

Medicine, Oncology, Pharmacotherapy +17

LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3

Silke Gillessen, Ananya Choudhury, F. Saad et al. · Annals of Oncology · 2024 · 37 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study

Christof Vulsteke, H. Kaimakliotis, Pongwut Danchaivijitr et al. · Annals of Oncology · 2025 · 34 citations · Full text

Medicine, Oncology, Pharmacology +13

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

J. E. Rosenberg, M.D. Galsky, Thomas Powles et al. · ESMO Open · 2024 · 28 citations · Full text

Medicine, Oncology, Pharmacology +17

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

Michiel S. van der Heijden, Thomas Powles, Shilpa Gupta et al. · ESMO Open · 2025 · 11 citations · Full text

Medicine, Oncology, Pharmacology +14

1–5 of 5